Navigation Links
Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
Date:2/26/2016

MINNEAPOLIS, Feb. 26, 2016 /PRNewswire-USNewswire/ -- A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. A study to test the drug in humans has begun.

Huntington's disease is a rare, hereditary disease that causes uncontrolled movements, loss of intellectual abilities, emotional problems and eventually death. The disease is passed from parent to child through a mutation in the huntingtin gene. The mutation results in the production of a disease-causing huntingtin protein. Each child has a 50/50 chance of inheriting the gene mutation. Everyone who inherits the mutated gene will eventually develop the disease.

The new drug, called IONIS-HTTRx, is an antisense drug that acts as a "gene silencer" to inhibit the production of huntingtin protein in people with Huntington's disease.

"It is very exciting to have the possibility of a treatment that could alter the course of this devastating disease," said clinical study principal investigator Blair R. Leavitt, MD, of the University of British Columbia in Vancouver. "Right now we only have treatments that work on the symptoms of the disease." Leavitt notes the drug is still years away from being used in human clinical practice.

Earlier studies in mouse models of Huntington's disease showed that treatment with antisense drugs delays disease progression and results in sustained reversal of the disease phenotype. In YAC128 mice, a transgenic model of HD, motor deficits improved within one month of initiating antisense treatment and were restored to normal at two months after treatment termination. Motor skills of antisense-treated BACHD mice, another transgenic model of HD, improved eight weeks after initiation of treatment and persisted for at least nine months after treatment termination. In monkeys, dose-dependent reductions in HTT mRNA and Htt protein throughout the central nervous system were observed after intrathecal administration of an antisense drug. Reduction of cortical huntingtin levels by 50 percent was readily achieved in monkeys and correlated with 15 to 20 percent reduction in the caudate. In further tests in rodents and monkeys, IONIS-HTTRx was found to be well-tolerated without any dose-limiting side effects. 

The drug is now in a Phase 1/2a clinical study. The drug is delivered into the cerebral spinal fluid via an intrathecal injection in the lumbar space, as antisense drugs do not cross the blood brain barrier. In the current clinical study, the drug is administered in four doses at monthly intervals. Different doses of the drug will be evaluated for safety and tolerability. In addition, drug pharmacokinetics will be characterized and effects of the drug on specific biomarkers and clinical outcomes will be examined. 

The drug was developed by scientists at Ionis Pharmaceuticals in collaboration with their partners CHDI Foundation, Roche Pharmaceuticals and academic collaborators at University of California, San Diego. The preclinical studies were conducted by Ionis Pharmaceuticals. The ongoing clinical study is supported by Ionis Pharmaceuticals and is part of Ionis' collaboration with Roche to develop antisense drugs to treat Huntington's disease.

Learn more about Huntington's disease at www.aan.com/patients.

The American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

 


'/>"/>
SOURCE American Academy of Neurology
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity
2. Ameritox Research Confirms Significant Spike in Potential Nonadherence to Opioid Medications
3. Ameritox Data on ADHD Stimulant Prescriptions Uncovers Significant Rates of Illicit Drug Use and Potential Nonadherence to Drug Regimen
4. Eisais Lenvatinib Receives FDA Priority Review for the Potential Treatment of Advanced Renal Cell Carcinoma in Combination with Everolimus
5. Largest Breast Cancer Study of its Kind Suggests Several New Potential Drug Targets and Combinations
6. U.S. and European Regulators Accept Applications for AbbVies Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia
7. Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms
8. Phoenix PharmaLabs Releases New Data Confirming That Their Novel Opioid Shows No Signs of Addiction Potential
9. U-M startup company secures license, funding to test potential drugs aimed at endocrine disorders
10. Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
11. Caris Life Sciences Non-Invasive Liquid Biopsy Platform ADAPT Biotargeting System Demonstrates Potential to Improve Accuracy of Breast Cancer Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... (PRWEB) , ... January 10, 2019 , ... ... to introduce the new A-Series Advantage Anesthesia Delivery platform, providing a modular, state-of-the-art ... A7 Advantage systems, enabling Mindray to continue its unwavering commitment to perioperative care. ...
(Date:1/8/2019)... , ... January 08, 2019 , ... ... been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. ... System and demonstrated a commitment to exemplary care for men suffering from symptoms ...
(Date:1/8/2019)... ... January 08, 2019 , ... “A baby is born ... can change that alarming statistic,” said Christina Chambers, PhD, MPH, President of MotherToBaby, ... is joining with leading prenatal health experts from the National Birth Defects Prevention ...
Breaking Medicine Technology:
(Date:1/15/2019)... ... January 15, 2019 , ... Ophthalmic Consultants of Long ... office to a new, larger space at 70 East Sunrise Highway, Suite 400, Valley ... needs of its patients. , According to Gerard D’Aversa, MD, “After serving the Valley ...
(Date:1/14/2019)... ... , ... After many months of preparation, the providers and staff at San ... Asthma. This new allergy and asthma clinic is conveniently located in the heart of ... any immunological and respiratory medical care needs. , In the new allergy and asthma ...
(Date:1/14/2019)... ... January 14, 2019 , ... Yes, the Millennials love their Bluetooth ... Council on Active Aging® (ICAA), new tech is also finding a home in senior ... , queried respondents from a variety of organizations that work with older adults about ...
(Date:1/14/2019)... ... January 15, 2019 , ... Early bird pricing for Medical Device Risk ... is just plain hard, complicated, conflicted, confusing. And it is getting even more complicated ... not intended as “major”, the new standard adds new definitions, changes the clause numbering, ...
(Date:1/14/2019)... ... January 14, 2019 , ... ... and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human]) for post-exposure prophylaxis ... In the update, the CDC notes that VARIZIG is commercially available from a ...
Breaking Medicine News(10 mins):